Nontoxic hydrogel for breast cancer treatment

December 4, 2013
Nontoxic hydrogel for breast cancer treatment
When the anticancer drug Herceptin is delivered to mice via a slow-release, nontoxic hydrogel (left), it localizes to tumors for a sustained period of at least two weeks (right). Credit: WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

A nontoxic hydrogel developed by the A*STAR Institute of Bioengineering and Nanotechnology and IBM Research offers a new way forward for breast cancer therapeutics.

Breast cancer is the most common form of invasive cancer affecting women worldwide. Treatment usually involves surgery followed by a course of either chemotherapy, radiotherapy or hormone therapy designed to reduce the risk of the cancer's recurrence. In recent years, however, targeted drugs have increasingly become an effective option to fight the disease.

One such is Herceptin, also known as trastuzumab, a monoclonal antibody that can slow or even halt tumor growth in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer—a particularly fast-growing form of the disease that affects one in four patients. Typically, the drug is administered at a clinic through an intravenous drip, a process that can take up to 90 minutes. A major drawback of this method of delivery is that without frequent follow-up doses, Herceptin loses its effectiveness. Therefore, patients are commonly required to visit the clinic on a weekly basis.

Now, a team of researchers from the A*STAR Institute of Bioengineering and Nanotechnology (IBN) and IBM Research led by Yi Yan Yang and James Hedrick has developed a more efficient way of delivering Herceptin to breast cancer cells. The approach promises to improve the effectiveness of treatment for the HER2-positive form of the disease. Drawing on IBN's expertise in the development of novel biomaterials, the researchers recognized the advantages of using a hydrogel—comprising 96 per cent water and a uniquely designed polymer—as a carrier for Herceptin in the body.

The hydrogel is nontoxic, biodegradable and can be injected under the skin without causing an inflammatory response. By varying the composition and concentration of the polymer, the researchers were able to fine-tune the hydrogel's properties to ensure a slow and sustained release of the anticancer drug, thus increasing the efficiency of delivering the drug to the target site. Correspondingly, use of the hydrogel for drug delivery has the potential to reduce the frequency at which patients need to be injected with Herceptin from once a week to once every four weeks.

Recently, the researchers conducted studies in mice, which confirmed that their Herceptin-loaded hydrogel delivers the drug efficiently, before it degrades within 6 weeks. They found that 4 weeks after injection, tumors in the mice had decreased in size by as much as 77 per cent. The researchers say that their next goal will be to conduct clinical trials in humans, in conjunction with industrial partners.

Other teams at IBN are also exploring the innovative use of hydrogels for controlled-release drug delivery to tackle different types of cancer (see Greater anticancer potency with less risk). The institute has always cultivated a multi-pronged approach toward cancer research, notes Jackie Y. Ying, professor and executive director at IBN.

"Our multidisciplinary research teams are working with various industrial, clinical and academic partners to develop new materials and tools to improve cancer diagnosis and treatment," she adds. "This latest breakthrough with our long-term partner IBM Research promises more efficient administration of anti-cancer drugs and more effective treatment of breast cancer, which we hope will benefit patients worldwide."

Explore further: Hydrogel improves delivery of anti-cancer drug

Related Stories

Hydrogel improves delivery of anti-cancer drug

November 1, 2013
The Institute of Bioengineering and Nanotechnology (IBN) and IBM Research (IBM) have developed a new non-toxic hydrogel that is capable of shrinking breast cancer tumors more rapidly than existing therapies. As described ...

Study explains why drug may help more cancer patients

November 18, 2013
(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...

New therapy for HER2-positive breast cancer developed

July 26, 2011
Patients with HER2-positive breast cancer may soon have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research.

New research challenges notion of using Herceptin only for HER2-positive breast cancer

February 26, 2013
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that the drug Herceptin, ...

Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment

July 19, 2012
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start ...

Recommended for you

Clear link between heavy vitamin B intake and lung cancer

August 22, 2017
New research suggests long-term, high-dose supplementation with vitamins B6 and B12—long touted by the vitamin industry for increasing energy and improving metabolism—is associated with a two- to four-fold increased lung ...

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.